stockrowCabot Corporation
CBT Basic Materials Specialty Chemicals
Cabot Corporation’s revenue for fiscal 2025 (year ended September 2025) was $3.7 billion, down 7.04% from fiscal 2024.
- Revenue
- +12.2%
- EPS
- +79.4%
- Free cash flow
- −51.7%
- Total debt
- +10.8%
Quarter to September 2026, against a year earlier
Follow CBT
Alert me
Cabot Corporation (CBT) Return on equity
Cabot Corporation's return on equity over the twelve months to 30 September 2026 was 12.2%, down 7.9 percentage points from fiscal 2025 (20.1%). Over the past ten years it has ranged from −24.4% (fiscal 2020) to 36.5% (fiscal 2023); the current reading is higher than 73% of that period. That is above the Specialty Chemicals industry median of 2.34% and above the Basic Materials sector median of 0.00%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 20.1% | (5.27) |
| FY2024 | 25.4% | (11.13) |
| FY2023 | 36.5% | 16.79 |
| FY2022 | 19.7% | (6.56) |
| FY2021 | 26.3% | 50.70 |
| FY2020 | −24.4% | (37.45) |
| FY2019 | 13.0% | 20.86 |
| FY2018 | −7.85% | (24.40) |
| FY2017 | 16.6% | 5.78 |
| FY2016 | 10.8% | 30.41 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| WDFC WD-40 Company compare | 30.4% |
| HWKN Hawkins, Inc. compare | 16.0% |
| AVNT Avient Corporation compare | 15.0% |
| SXT Sensient Technologies Corporation compare | 13.7% |
| CLMT Calumet, Inc. compare | 12.7% |
| CBT Cabot Corporation | 12.2% |
| FUL H. B. Fuller Company compare | 9.58% |
| PRM Perimeter Solutions, SA compare | 4.55% |
| ASH Ashland Inc. compare | 0.00% |
| Specialty Chemicals industry median | 2.34% |
| Basic Materials sector median | 0.00% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on CBT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement